Biohaven Pharmaceutical Holding (NYSE:BHVN) and Medison Pharma announce an agreement to distribute NURTEC ODT (rimegepant) in Israel.
NURTEC ODT is the first and only calcitonin
gene-related peptide receptor antagonist available in a fast-acting
orally disintegrating tablet approved for the acute treatment of
migraine.
https://seekingalpha.com/news/3561264-biohaven-inks-distribution-deal-for-nurtec-odt
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.